Efficient non-viral engineering of immune cells for cell therapy using circular single-stranded DNA

Hao Wu

13 January 2025

Viewpoint

Gene delivery: persistent challenges call for a reference measure

Max Ryadnov

22 October 2024

Viewpoint

Pioneering the future of non-viral genome engineering

Hao Wu

18 September 2024

Viewpoint

Expanding the therapeutic index of lipid nanoparticles: potential key for clinical translation success

Zhenghong Gao

12 June 2024

Viewpoint

Best practices and considerations for outsourcing with CDMOs

Joseph W Graskemper

11 April 2024

Viewpoint

The current viral vector characterization landscape: from navigating evolving regulatory guidance to leveraging analytical tools for process development

Ning Ding

08 December 2023

Viewpoint

Scale-up and automation of iPSC-derived cell therapy manufacturing

Dhruv Sareen, Jonathan Rodriguez, Hojae Lee

05 October 2023

Viewpoint

Harnessing the untapped potential of commensal viruses in genetic medicine

Joseph Cabral

04 May 2023

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Raquel Martín-Ibáñez

26 April 2023

Viewpoint

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Danielle Steele

17 April 2023

Viewpoint

Transfection optimization for AAV production

Peter Boyce

03 April 2023

Viewpoint

The present hurdles and opportunities in our knowledge of AAV basic biology

Bijay Dhungel, John Rasko

17 May 2022

Viewpoint

Overcoming the immune-related shortfalls of AAV

Genine Winslow

10 May 2022

Viewpoint

Future trends in viral vector process & product development

Ramji Krishnan

28 April 2022

Viewpoint

Considerations for demonstrating comparability of AAV processes

Laura Giersch

26 April 2022

Viewpoint

Titration for research grade rAAV: understanding challenges and minimum requirements

Javier F Alcudia

06 December 2021

Viewpoint

From start-up to scale-up: a journey through AAV process development

Kevin Mouillesseaux

05 October 2021

Viewpoint

Viral vector gene delivery: balancing safety, efficacy and dose

Thijs Gerritzen

01 October 2021

Viewpoint

Overview of major AAV production platforms

Jote Bulcha

24 September 2021

Viewpoint

Recent evolution in Process Analytical Technology for viral vectors

Tony Bou Kheir

20 August 2021

Viewpoint

The dose makes the poison: next generation AAV vectors can save the day

Julia Fakhiri, Jihad El Andari

13 July 2021

Viewpoint